EUVIMEDΑνακαλύψτε το EUVIMED
Open access · CC BY 4.0

Improving Bioprocess Conditions for the Production of Prodigiosin Using a Marine Serratia rubidaea Strain

Ricardo F S Pereira iD, Carla C C R de Carvalho iD

Marine Drugs · 2024

DOI: 10.3390/md22040142 ↗

At a glance

Journal article in Marine Drugs, 2024. Written by Ricardo F S Pereira and 1 co-authors. Institution: Department of Bioengineering, iBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais,…. Major MEDLINE topics: Prodigiosin, Bioreactors, Serratia, Culture Media. Cited 15 times so far (Crossref); 82 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Commission, Fundação para a Ciência e Tecnologia, European Union’s Horizon 2020 Research and Innovation Programme.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

The enormous potential attributed to prodigiosin regarding its applicability as a natural pigment and pharmaceutical agent justifies the development of sound bioprocesses for its production. Using a Serratia rubidaea strain isolated from a shallow-water hydrothermal vent, optimization of the growth medium composition was carried out. After medium development, the bacterium temperature, light and oxygen needs were studied, as was growth inhibition by product concentration. The implemented changes led to a 13-fold increase in prodigiosin production in a shake flask, reaching 19.7 mg/L. The conditions allowing the highest bacterial cell growth and prodigiosin production were also tested with another marine strain: S. marcescens isolated from a tide rock pool was able to produce 15.8 mg/L of prodigiosin. The bioprocess with S. rubidaea was scaled up from 0.1 L shake flasks to 2 L bioreactors using the maintenance of the oxygen mass transfer coefficient (kLa) as the scale-up criterion. The implemented parameters in the bioreactor led to an 8-fold increase in product per biomass yield and to a final concentration of 293.1 mg/L of prodigiosin in 24 h.

Subjects

MeSH terms (MEDLINE)

ProdigiosinBioreactorsSerratiaCulture MediaBiomassOxygenTemperatureAquatic Organisms

Author keywords

Serratia marcescensSerratia rubidaeabioreactorskLamedium engineering

Substances

ProdigiosinCulture MediaOxygen

Authors and institutions

  • Department of Bioengineering, iBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.

ORCID profiles: Ricardo F S Pereira, Carla C C R de Carvalho

Funding

  • European Commission
  • Fundação para a Ciência e Tecnologia
  • European Union’s Horizon 2020 Research and Innovation Programme
  • Fundação para a Ciência e a Tecnologia (FCT, Portugal)
  • Research Unit iBB—Institute for Bioengineering and Biosciences
  • i4HB—Associate Laboratory Institute for Health and Bioeconomy

Cite

APA

Pereira, R. F. S., & de Carvalho, C. C. C. R. (2024). Improving Bioprocess Conditions for the Production of Prodigiosin Using a Marine Serratia rubidaea Strain. Marine Drugs. https://doi.org/10.3390/md22040142

Vancouver

Pereira RFS, de Carvalho CCCR. Improving Bioprocess Conditions for the Production of Prodigiosin Using a Marine Serratia rubidaea Strain. Marine Drugs. 2024. doi:10.3390/md22040142

BibTeX
@article{Pereira2024,
  author = {Pereira, Ricardo F S and de Carvalho, Carla C C R},
  title = {Improving Bioprocess Conditions for the Production of Prodigiosin Using a Marine Serratia rubidaea Strain},
  journal = {Marine Drugs},
  year = {2024},
  doi = {10.3390/md22040142}
}
Start for free →